CancerDrs

Lung Cancer clinical trials in Alabama

25 actively recruiting lung cancer trials at 10 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Alabama:
  • Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama
  • University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Alabama:
  • Alabama Oncology, Shelby — Alabaster, Alabama
  • Alabama Oncology, Bessemer — Bessemer, Alabama
  • Alabama Oncology, St Vincent's Birmingham — Birmingham, Alabama
  • Alabama Oncology, Brookwood — Birmingham, Alabama
  • Alabama Oncology, Princeton — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Alabama:
  • Local Institution - 0347 — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Alabama:
  • University of Alabama at Birmingham - Main /ID# 247074 — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Alabama:
  • Southern Cancer Center Pc — Daphne, Alabama
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Alabama:
  • Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…

Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Alabama:
  • Central Alabama Research — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Alabama:
  • Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063 — Birmingham, Alabama
  • Usa Mitchell Cancer Institute /ID# 280198 — Mobile, Alabama
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Sponsor: Eikon Therapeutics
NCT ID: NCT07365319
Sites in Alabama:
  • Southern Cancer Center, P.C. — Daphne, Alabama
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Alabama:
  • Central Alabama Research ( Site 0108) — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Alabama:
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland — Saraland, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Alabama:
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland — Saraland, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the effic…

Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT06773910
Sites in Alabama:
  • Southern Cancer Center — Daphne, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in th…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04665739
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung…

Sponsor: Daiichi Sankyo
NCT ID: NCT06362252
Sites in Alabama:
  • University of Alabama -Birmingham — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor mic…

Sponsor: Krystal Biotech, Inc.
NCT ID: NCT06228326
Sites in Alabama:
  • XCancer Research Network/Dothan Hematology & Oncology — Dothan, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-sm…

Sponsor: Pfizer
NCT ID: NCT07489066
Sites in Alabama:
  • Clearview Cancer Institute (Crestwood) — Huntsville, Alabama
  • Clearview Cancer Institute — Huntsville, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , N…

Sponsor: Advenchen Pharmaceuticals, LLC.
NCT ID: NCT05363280
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Alabama:
  • The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
  • The University of Alabama at Birmingham — Birmingham, Alabama
  • University of Alabama at Birmingham - Phase I Clinical Trials Unit — Birmingham, Alabama
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama:
  • Massive Bio SYNERGY-AI site — Birmingham, Alabama
  • Massive Bio SYNERGY-AI site — Mobile, Alabama
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of South Alabama — Mobile, Alabama
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17